var title_f9_4_9280="Vaginal tubal sterilization E";
var content_f9_4_9280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal tubal sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9280=[""].join("\n");
var outline_f9_4_9280=null;
var title_f9_4_9281="Uchida tubal ligation A";
var content_f9_4_9281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uchida technique of sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9281=[""].join("\n");
var outline_f9_4_9281=null;
var title_f9_4_9282="SC central line infra mid";
var content_f9_4_9282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Infraclavicular approach to the subclavian vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The midpoint approach to cannulation of the subclavian vein is most common. Insert the needle 2 to 3 cm inferior to the midpoint of the clavicle. Advance the needle aiming just deep to the suprasternal notch, keeping the needle parallel to the ground.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9282=[""].join("\n");
var outline_f9_4_9282=null;
var title_f9_4_9283="ECG tutorial: Physiology of the conduction system";
var content_f9_4_9283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Physiology of the conduction system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9283/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9283/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9283/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9283/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9283/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9283/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/4/9283/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac conduction system is designed for electrical impulse creation and propagation. It allows for initiation of impulses in the atrium, slowed conduction in the atrioventricular node (AV node), and rapid propagation through the His-Purkinje system to allow synchronous contraction in the ventricles. Layers of redundancy occur, so that if one portion is damaged, there may be other areas that can compensate for the loss of function.",
"   </p>",
"   <p>",
"    Cardiac cells have the inherent property of spontaneous depolarization, which creates the cardiac impulse. Cells within the sinus node have the fastest rate of spontaneous depolarization, and, therefore, the sinus node is the main pacemaker region of the heart. The AV node has the second fastest rate of spontaneous depolarization, which allows it to create an escape rhythm if the sinus node is diseased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATRIAL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinus node (the most proximal part of the conduction system) exhibits the most automaticity and functions as the dominant pacemaker in normal circumstances. This structure generates a slow action potential, mediated by calcium currents, that exits the node and activates the atrial myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .) The atrial myocardium action potential has a rapid upstroke, mediated by sodium ions (",
"    <a class=\"graphic graphic_figure graphicRef61989 \" href=\"UTD.htm?34/63/35827\">",
"     figure 1",
"    </a>",
"    ) that help to quickly transmit the signal.",
"   </p>",
"   <p>",
"    Several preferential tracts exist in the atria to more quickly spread electrical signals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9283/abstract/1\">",
"     1",
"    </a>",
"    ]. In the right atrium, these include the crista terminalis and pectinate muscles. The Bachman bundle begins anterior to the superior vena cava and crosses the superior interatrial septum to facilitate right to left atrial conduction. A superior pulmonary bundle and septo-atrial bundle speed conduction in the left atrium.",
"   </p>",
"   <p>",
"    As the atrium is depolarized, a \"P\" wave is transcribed on the surface ECG (",
"    <a class=\"graphic graphic_figure graphicRef59933 \" href=\"UTD.htm?1/61/2006\">",
"     figure 2",
"    </a>",
"    ). Since the sinus node is in the superior right atrium, the signal goes from superior to inferior, anterior to posterior, and right to left. The P wave is upright and slightly notched in all of the limb leads, with the exception of aVR which has a negative P wave. The precordial leads also show an upright P wave, although in leads V1 and V2 the P wave is usually biphasic; an initial positive followed by a negative deflection reflects depolarization of the right atrium (which is anterior) and then the left atrium (which is posterior).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ATRIOVENTRICULAR NODE AND BUNDLE OF HIS ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After atrial activation, the impulse reaches the AV node. This structure generates a slow calcium mediated action potential (",
"    <a class=\"graphic graphic_figure graphicRef61989 \" href=\"UTD.htm?34/63/35827\">",
"     figure 1",
"    </a>",
"    ). Thus, there is a delay in impulse transmission through this structure.",
"   </p>",
"   <p>",
"    Once the action potential traverses the AV node, it activates the proximal portion of the bundle of His, a specialized conducting tissue that generates a fast action potential. Thus, impulse conduction through this structure is rapid. This period of time from the end of the P wave to the beginning of the QRS, during which there is activation of both the atrioventricular node and bundle of His, is termed the PR segment. The PR interval, in contrast, includes the P wave (atrial activation) as well as the PR segment (",
"    <a class=\"graphic graphic_figure graphicRef59933 \" href=\"UTD.htm?1/61/2006\">",
"     figure 2",
"    </a>",
"    ). Because the AV node and bundle of His are small, there is no electrical activity manifest on the surface ECG from their conduction. The electrical activity that is occurring during the PR interval can be measured, however, using intracardiac electrodes during electrophysiologic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    .) Abnormalities of conduction in the AV node and bundle of His are manifest on the surface ECG as first, second, or third degree AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VENTRICULAR ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After impulse transmission through the bundle of His, the impulse is conducted to the right and left bundle branches; these are extensions of the His bundle that generate a fast action potential (",
"    <a class=\"graphic graphic_figure graphicRef61989 \" href=\"UTD.htm?34/63/35827\">",
"     figure 1",
"    </a>",
"    ). The impulse travels through the bundles and the Purkinje fiber network, generating a fast action potential and resulting in rapid activation and depolarization of the myocardium of the right and left ventricles. The impulse enters the ventricular myocardium first from a septal portion of the left bundle. Thus, the left intraventricular septum is the first part of the ventricle to become depolarized, resulting in the following ECG appearance of the QRS (",
"    <a class=\"graphic graphic_figure graphicRef59933 \" href=\"UTD.htm?1/61/2006\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial small septal Q wave on the surface ECG leads that measure electrical activity toward the left side of the heart (leads I, aVL and V4 to V6) since the impulse is moving away from these leads.",
"     </li>",
"     <li>",
"      A small initial R wave in the leads pointed toward the right side of the heart (aVR, V1 and V2) since the impulse is moving in the direction of these leads (",
"      <a class=\"graphic graphic_figure graphicRef61989 \" href=\"UTD.htm?34/63/35827\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the mass of the left ventricle is much greater than that of the right, the normal ECG primarily reflects left ventricular depolarization (",
"    <a class=\"graphic graphic_figure graphicRef59933 \" href=\"UTD.htm?1/61/2006\">",
"     figure 2",
"    </a>",
"    ). The impulse spreads from the septum to the lateral wall in a right to left and superior to inferior direction, thereby generating the following ECG appearance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tall upright R wave in the limb leads I, II, aVF and the precordial leads V3 to V6 since the impulse is moving towards these leads.",
"     </li>",
"     <li>",
"      A deep negative deflection or S wave in the leads that are directed to the septum and right side of the heart (aVR, V1, and V2) since the impulse is moving away from these leads.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last part of the left ventricle to become depolarized is the high lateral region. Thus, the last part of the QRS may be reflected on the surface ECG as a small terminal S wave in leads I, II, aVF and V4 to V6, and a small r' in lead aVR and occasionally V1 and V2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REPOLARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the entire myocardium of the left and right ventricles completes depolarization, there is a period of time immediately prior to the final phase of repolarization or recovery during which there is no apparent electrical activity on the surface ECG, the isoelectric ST segment phase. During this period, corresponding to phase 2 of the action potential, the ventricular myocytes are at about the same potential, so no net current flow occurs. Thereafter, the ventricular myocardium undergoes the final phase of repolarization, generating a T wave on the surface ECG (",
"    <a class=\"graphic graphic_figure graphicRef59933 \" href=\"UTD.htm?1/61/2006\">",
"     figure 2",
"    </a>",
"    ). Since the wave of repolarization occurs from the epicardium to the endocardium and is of opposite electrical charge as depolarization, it is usually positive on the ECG. The last wave form in this cycle, usually most apparent in the mid-precordial leads, is the U wave, which is of uncertain origin but may represent repolarization of the His-Purkinje system or of the mid-myocardial M cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105550839\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac cells possess inherent spontaneous automaticity. The tissue that possesses the greatest degree of automaticity (eg, has the fastest rate of spontaneous depolarization) functions as the dominant pacemaker; it generates a spontaneous action potential that is conducted along the rest of the conduction system, activating the myocardium in a uniform fashion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sinus node exhibits the fastest automaticity and initiates each beat in most cases. Electrical activity spreads from the sinus node to the atrium, causing a P wave on the electrocardiogram (ECG). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Atrial activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After atrial activation, the impulse reaches the atrioventricular node (AV node). There is relatively slow transmission of the electrical current here. Once the action potential traverses the AV node, it activates the proximal portion of the bundle of His. Although there is no manifestation of AV nodal or bundle of His activation on the surface ECG, conduction through these structures occurs during the PR segment. The PR interval, which also includes atrial conduction, is comprised of the P wave as well as the PR segment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Atrioventricular node and bundle of His activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sequential activation of different parts of the left and right ventricles follows and causes the characteristic QRS complex. As the left ventricular muscle mass is far greater than that of the right ventricle, the QRS complex primarily represents left ventricular depolarization.",
"     </li>",
"     <li>",
"      After the QRS, the ventricular myocytes normally remain at about the same potential, so the surface ECG returns to baseline-ST segment phase. Thereafter, the ventricular myocardium undergoes the final phases repolarization, generating a T wave and sometimes a small U wave. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Repolarization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12261142\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9283/abstract/1\">",
"      Zhao J, Butters TD, Zhang H, et al. An image-based model of atrial muscular architecture: effects of structural anisotropy on electrical activation. Circ Arrhythm Electrophysiol 2012; 5:361.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2116 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9283=[""].join("\n");
var outline_f9_4_9283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H105550839\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATRIAL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ATRIOVENTRICULAR NODE AND BUNDLE OF HIS ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VENTRICULAR ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REPOLARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105550839\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12261142\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2116|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/63/35827\" title=\"figure 1\">",
"      Conduction system action potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/61/2006\" title=\"figure 2\">",
"      Major deflections on ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_4_9284="Erythema multiforme tongue";
var content_f9_4_9284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhagic crusting and mucosal erosions involving the lips and tongue in a patient with erythema multiforme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9284=[""].join("\n");
var outline_f9_4_9284=null;
var title_f9_4_9285="Recipro gait orthosis";
var content_f9_4_9285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reciprocating gait orthosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A child with myelomeningocele using a reciprocating gait orthosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9285=[""].join("\n");
var outline_f9_4_9285=null;
var title_f9_4_9286="Abscess associated with hand infection";
var content_f9_4_9286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abscess associated with hand infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph demonstrates a dorsal subcutaneous abscess. Note that the abscess is pointing, meaning that the skin is starting to thin from the pressure of the fluid underneath, which indicates impending rupture of the abscess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9286=[""].join("\n");
var outline_f9_4_9286=null;
var title_f9_4_9287="Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors";
var content_f9_4_9287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9287/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9287/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9287/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9287/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/4/9287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a class of potent oral antiretroviral (ARV) drugs. One member of this class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , is currently a preferred first-line agent for antiretroviral-na&iuml;ve patients according to several treatment guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are currently five approved NNRTIs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    ). Efavirenz, rilpivirine and nevirapine are predominantly used in treatment-na&iuml;ve patients, while etravirine is indicated for treatment-experienced patients. Due to its less favorable pill burden, dosing frequency, and adverse event profile, delavirdine is rarely used. This topic will summarize the comparative clinical trial data in both treatment-naive and treatment-experienced patients supporting the use of these agents in various patient populations.",
"   </p>",
"   <p>",
"    Information regarding selecting antiretroviral regimens, toxicity, and dosing is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral treatment (ART) regimens should have at least three active antiretroviral medications. In treatment-na&iuml;ve patients, recommended therapy will have two nucleoside reverse transcriptase inhibitors (NRTIs) (one of them",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ) and a third active drug consisting of either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major advantages of the NNRTIs are their relative potency and low pill burden, the latter especially notable with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , which can be given co-formulated with the NRTIs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    as one pill daily. A major disadvantage for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    , and efavirenz is that a single resistance mutation can lead to complete loss of antiviral activity; this property is sometimes referred to as a \"low genetic barrier\" to resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another shared aspect of NNRTIs is that all available agents have a relatively high incidence of rash. These rashes are generally mild and resolution is common even with continued dosing. However, sometimes the rash can be severe enough to warrant drug cessation. At the extreme end of rash severity, all NNRTIs have rarely been associated with Stevens Johnson syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    maintains activity in viral isolates with some existing NNRTI mutations. Importantly, this includes K103N, the most common resistance mutation selected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    . Resistance to etravirine is cumulative with increasing numbers of etravirine-associated resistance mutations, the most common of which are Y181C and G190A. At least three mutations are required for clinically significant resistance. Detailed information regarding resistance patterns and etravirine is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are distinct side effect profiles for each of these drugs that also need to be considered prior to dosing. For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is associated with central nervous system (CNS) side effects such as headache, irritability, depression, and somnolence; these usually clear or improve by the third week of treatment. The most important",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -related side effect is a hypersensitivity syndrome that consists of fever, rash, and hepatotoxicity; not all components are present in every case. The risk of hypersensitivity is higher in patients with a relatively preserved CD4 cell count. Consequently, nevirapine is not recommended in women with CD4 counts &gt;250 and men with CD4 counts &gt;400",
"    <span class=\"nowrap\">",
"     mL/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    A detailed discussion of adverse events associated with all of the NNRTIs is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for the selection of antiretroviral regimens in the individual patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abbreviations used",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table lists commonly used abbreviations for the antiretroviral agents discussed in this topic (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"UTD.htm?24/25/24989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT-NAIVE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies that have directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . The largest was the 2NN study, which is discussed below.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    has only been directly compared with efavirenz.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efavirenz and nevirapine (2NN study)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized open-label trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    600 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    400 mg daily, nevirapine 200 mg twice daily, and efavirenz 800 mg daily plus nevirapine 400 mg daily in 1216 treatment-naive patients who also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T) 40 mg twice daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (3TC) 150 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/1\">",
"     1",
"    </a>",
"    ]. The primary endpoint was the proportion of patients with treatment failure, which was a combined primary end point of virologic failure, disease progression or change of treatment.",
"   </p>",
"   <p>",
"    After 48 weeks of follow-up, there was a trend toward fewer patients experiencing treatment failure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    than with once-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , twice-daily nevirapine, or combined therapy (38 versus 44, 44, and 53 percent, respectively). There were no significant differences among the regimens in reducing viral load or increasing CD4 cell counts.",
"   </p>",
"   <p>",
"    A post-hoc analysis was performed to determine if baseline CD4 cell counts or HIV RNA levels affected the efficacy of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    - based therapy in the 2NN trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of virologic failure was increased in patients with a CD4 count &lt;25",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    compared to those with a CD4 count &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (HR 1.28, 95% CI 0.93-1.77). Similarly, virologic failure was increased in patients with an HIV RNA level &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    compared to lower viral loads (HR 1.2, 95% CI 0.96-1.50). Both nevirapine and efavirenz performed equally well within these strata. However, nevirapine was associated with an increased risk of rash in patients with higher CD4 cell counts, particularly in women with a CD4 cell count &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Four-drug therapy was associated with more toxicity without incremental clinical benefit. Two deaths among the study population were attributed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , one due to hepatotoxicity and one to Stevens-Johnson syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H658623\">",
"    <span class=\"h2\">",
"     Efavirenz versus rilpivirine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two controlled trials (ECHO and THRIVE) compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in treatment-naive patients in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In ECHO, all study participants were assigned",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    while in THRIVE the NRTI background was selected by the investigator from three possible options (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ). In both trials, randomization was stratified by screening viral load. In the THRIVE trial, randomization was also stratified by NRTI background. At baseline, the median CD4 cell count was approximately 250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and the median HIV RNA 100,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The pooled results (n = 1368 patients) demonstrated non-inferiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , with the proportion of patients attaining viral suppression at 48 weeks comparable in both arms (83 versus 80 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, adverse events (including rash and central nervous system side effects) were less common with rilpivirine than efavirenz and there were significantly fewer drug discontinuations with rilpivirine due to adverse events. Increases in plasma lipids were significantly lower with rilpivirine compared to efavirenz through 48 weeks of follow-up.",
"   </p>",
"   <p>",
"    Increases in CD4 cell counts were comparable between arms. Response rates to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    were stratified according to baseline viral load. In the low viral load stratum, the proportion of patients achieving viral suppression was higher with rilpivirine (90 versus 84 percent, respectively), while the converse was true for those with viral loads &gt;100,000 (77 versus 81 percent for rilpivirine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , respectively).",
"   </p>",
"   <p>",
"    Furthermore, patients who developed virologic failure on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    were more likely to develop",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"      lamivudine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"      emtricitabine",
"     </a>",
"     -associated",
"    </span>",
"    mutations and cross-resistance to other non-nucleoside reverse transcriptase inhibitors (NNRTIs) than patients who had virologic failure on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    . The NNRTI resistance mutations selected by rilpivirine included the E183K mutation, known to confer cross resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , a drug that still can be used in many patients who fail treatment with efavirenz. In addition, patients with virologic failure on rilpivirine had a higher risk of developing a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog mutation (eg, M184V) than among those patients who developed virologic failure on efavirenz [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    are generally comparable in virologic outcomes, efavirenz is usually selected as the preferred drug compared with nevirapine. This is due to a more favorable toxicity profile and a substantially larger body of clinical trials data supporting its antiviral activity and tolerability. However, nevirapine is preferred for use during pregnancy or in women planning to conceive, due to the associated teratogenicity of efavirenz.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    is overall better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , but virologic failure is more common, especially in those with a baseline viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Its use should generally be limited to those beginning therapy with a viral load below this threshold. &nbsp;",
"   </p>",
"   <p>",
"    Potential adverse events and advice regarding the appropriate selection of non-nucleoside reverse transcriptase inhibitors as part of combination ART is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT-EXPERIENCED PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Switch strategies (NEFA study)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NEFA study was designed to assess whether patients who had viral suppression on a protease inhibitor (PI)-containing ART could be successfully switched to an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    -,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -containing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who developed virologic failure underwent further analysis for evolution of drug resistance.",
"   </p>",
"   <p>",
"    Of the 460 patients included in the study, 51 (11 percent) experienced virological failure after 24 months of follow-up. A higher percentage of patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    arm developed resistance (17 percent) compared with lower rates of resistance in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    arms (9 and 8 percent, respectively). Furthermore, a higher number of resistance mutations to one or more of the nucleoside analog drugs was observed in the abacavir arm than either of the non-nucleoside reverse transcriptase inhibitor (NNRTI) arms. The risk of virologic failure was particularly high among those with a prior history of nucleoside reverse transcriptase inhibitor (NRTI)-based therapy before beginning",
"    <span class=\"nowrap\">",
"     NRTI/PI",
"    </span>",
"    treatment.",
"   </p>",
"   <p>",
"    This study demonstrated that both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    perform well in switch strategies after treatment with a PI. In contrast, patients on the triple nucleoside analog arm had significantly more virologic failure; this approach is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10325?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other trials of switch strategies with NNRTIs are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Etravirine versus PI-based ART (TMC125-227 trial)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this trial, 116 PI-naive, but NNRTI-experienced patients with &ge; resistance mutations were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    or a PI-based regimen in addition to two nucleoside analogs of the investigator's choice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/7\">",
"     7",
"    </a>",
"    ]. The median baseline viral load was 4.32 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and the median baseline CD4 count was 229",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    After",
"    an initial viral load decline of 1.3 log at week 8, HIV RNA rebounded in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    arm compared with a continuous decline in the PI arm. In a multivariate analysis, the presence of primary NNRTI mutations (eg, K103N or Y181C) did not predict virologic response in the etravirine group. However, increasing numbers of nucleoside analog mutations were associated with increased risk of etravirine resistance.",
"   </p>",
"   <p>",
"    The results of this study demonstrate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    has some degree of cross-resistance with other NNRTIs, and, more importantly, should only be used when supported by other active drugs. Due to these findings, subsequent studies (eg, DUET-1 and DUET-2) incorporated the use of boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    in combination with etravirine with an optimized backbone nucleoside analog in an effort to improve virologic efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Etravirine in patients with drug resistance (DUET trials)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multinational double-blind, placebo-controlled phase III trial (DUET-1), 612 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    (200 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/8\">",
"     8",
"    </a>",
"    ]. Eligible patients were heavily treatment-experienced with documented NNRTI resistance and three or more primary protease inhibitor mutations. All patients also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and a nucleoside analog pair of the investigators' choice; use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    was optional.",
"   </p>",
"   <p>",
"    At week 24, a significantly higher proportion of patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    arm attained a viral load of &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    compared with those receiving placebo (56 versus 39 percent). In the subgroup of patients with no available active agents, a viral load below 50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was achieved by 21 (47 percent) of 45 patients in the etravirine group compared with 4 of 46 patients (9 percent) in the placebo group.",
"   </p>",
"   <p>",
"    Of the patients re-using or not using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    , more patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    arm attained viral suppression compared with the placebo group (55 versus 33 percent). Of the patients who used enfuvirtide de novo, viral suppression was achieved by similar proportions of patients in both etravirine and placebo groups (59 versus 56 percent).",
"   </p>",
"   <p>",
"    Side effects related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    were mild and consisted mainly of rash, which resolved with continued drug administration. A second similarly designed trial (DUET-2) confirmed the efficacy and safety of etravirine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Furthermore, the virologic superiority of etravirine was confirmed in the pooled 48-week analysis of DUET-1 and DUET-2 trial data; rash was the only adverse event to occur at a significantly higher incidence in the etravirine group (19 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9287/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the DUET studies is that they demonstrated, for the first time, that an NNRTI (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ) could add significant antiviral activity to a regimen, even after prior documented NNRTI treatment failure and resistance. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , the PI with the greatest activity against PI-resistant viruses, contributed to the overall excellent virologic outcomes despite the high degree of resistance in the study population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are currently five approved non-nucleoside reverse transcriptase inhibitors (NNRTIs):",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"       delavirdine",
"      </a>",
"      . Efavirenz, nevirapine, and rilpivirine are predominantly used in treatment-na&iuml;ve patients, while etravirine is indicated for treatment-experienced patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      is the preferred agent for treatment-naive patients due to its overall potency and favorable toxicity profile. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Efavirenz and nevirapine (2NN study)'",
"      </a>",
"      above.)&nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"       Rilpivirine",
"      </a>",
"      is better tolerated than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (less rash and CNS side effects), but should be reserved for use in those with viral loads &lt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      due to an increased risk of virologic failure and drug resistance in patients with higher levels of viremia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H658623\">",
"       'Efavirenz versus rilpivirine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      is used predominantly in resource-limited settings, where it is the preferred NNRTI for women who are pregnant or are considering pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Efavirenz and nevirapine (2NN study)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       Etravirine",
"      </a>",
"      is indicated as part of a regimen for treatment-experienced patients with prior treatment failure on NNRTI-based regimens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major advantages of NNRTIs are their relative potency and low pill burden. A major disadvantage of the NNRTI class is their low genetic barrier to resistance, where one mutation can lead to high-level resistance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large clinical trial demonstrated that both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      had similar efficacy in attaining viral suppression in treatment-naive patients; however, the toxicity profile of efavirenz was more favorable. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efavirenz and nevirapine (2NN study)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four-drug regimens using both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      have equal potency and more toxicity than three-drug regimens and are not recommended. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efavirenz and nevirapine (2NN study)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In treatment-experienced patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      in combination with an optimized background regimen containing boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      had greater virologic potency than a comparable regimen with placebo. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/1\">",
"      van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.",
"     </a>",
"    </li>",
"    <li>",
"     Vingerhoets J, Peeters M, Corbett C, et al. Presented at the 13th annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8th, 2006; abstract #154.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/3\">",
"      van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/4\">",
"      Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/5\">",
"      Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/6\">",
"      Ochoa de Echag&uuml;en A, Arnedo M, Xercavins M, et al. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 2005; 19:1385.",
"     </a>",
"    </li>",
"    <li>",
"     Woodfall B, Vingerhoets M, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227. The Eighth International Congress on Drug Therapy in HIV infection. November 12-16, 2006. Glasgow, UK. Abstract #PL5.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/8\">",
"      Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/9\">",
"      Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/10\">",
"      Hirschel B, Perneger T. No patient left behind--better treatments for resistant HIV infection. Lancet 2007; 370:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9287/abstract/11\">",
"      Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23:2289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3789 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9287=[""].join("\n");
var outline_f9_4_9287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abbreviations used",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT-NAIVE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efavirenz and nevirapine (2NN study)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H658623\">",
"      Efavirenz versus rilpivirine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT-EXPERIENCED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Switch strategies (NEFA study)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Etravirine versus PI-based ART (TMC125-227 trial)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Etravirine in patients with drug resistance (DUET trials)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/25/24989\" title=\"table 1\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10325?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_4_9288="Resting myocardial perfusion imaging in ischemia";
var content_f9_4_9288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Acute rest technetium 99m sestamibi myocardial perfusion imaging in myocardial ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute rest myocardial perfusion imaging (upper rows) in a 38-year-old white man evaluated in the emergency department for atypical chest pain and a nondiagnostic electrocardiogram. There is an inferior defect which resolves on rest images obtained after stabilization with medical therapy (arrow). Gated SPECT (panel A) revealed hypokinesis in the area of the defect and allowed rapid estimation of the systolic function. The patient underwent emergent coronary angiography for recurrence of chest pain with subsequent ST elevation in the inferior leads, and was found to have an occluded right coronary artery. Successful coronary angioplasty was performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Heller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9288=[""].join("\n");
var outline_f9_4_9288=null;
var title_f9_4_9289="Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients";
var content_f9_4_9289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Charles F Thomas, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Andrew H Limper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9289/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/4/9289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis pneumonia (PCP) is a potentially life-threatening infection that occurs in immunocompromised individuals. The nomenclature for the species of Pneumocystis that infects humans has been changed from Pneumocystis carinii to Pneumocystis jirovecii; this was done to distinguish it from the species that infects rats.",
"   </p>",
"   <p>",
"    HIV-infected patients with a low CD4 count are at the highest risk of PCP. Others at substantial risk include hematopoietic stem cell and solid organ transplant recipients; those with cancer (particularly hematologic malignancies); and those receiving glucocorticoids, chemotherapeutic agents, and other immunosuppressive medications.",
"   </p>",
"   <p>",
"    The treatment and prophylaxis of PCP in patients without HIV infection will be reviewed here. PCP in HIV-infected patients and the epidemiology, clinical manifestations, and diagnosis of PCP in non-HIV-infected patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) as the treatment of choice for PCP in non-HIV-infected patients (",
"    <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/1\">",
"     1",
"    </a>",
"    ]. Large randomized trials have proven the efficacy of TMP-SMX in patients with HIV infection, whereas efficacy in patients without HIV infection has only been shown in a few small observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] and one comparative randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard dose of TMP-SMX is 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously or orally daily in three or four divided doses (",
"    <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"     table 1",
"    </a>",
"    ). Dosing of TMP-SMX is based upon the TMP component and expressed as",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of TMP. Because TMP-SMX has excellent bioavailability, oral administration is appropriate for all patients who have a functioning gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative drugs for the treatment of mild to moderate PCP have been studied primarily in HIV-infected patients. For patients with mild or moderate PCP who are unable to tolerate TMP-SMX, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    (750 mg orally twice daily). Other regimens that may be used for mild to moderate PCP include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"     table 1",
"    </a>",
"    ). Patients should be tested for glucose-6-phosphate dehydrogenase deficiency before taking dapsone or primaquine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe PCP who have a contraindication to TMP-SMX should receive intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"     table 1",
"    </a>",
"    ). In a randomized trial of 50 patients with PCP, intravenous pentamidine (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily) was as effective as TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/5\">",
"     5",
"    </a>",
"    ]. However, pentamidine is not often used, since it is associated with greater toxicity (eg, hypotension, hypoglycemia, nephrotoxicity, and pancreatitis) and must be administered parenterally. We reserve intravenous pentamidine for patients with severe infection who are unable to tolerate TMP-SMX. We give intravenous pentamidine to patients with mild or moderate PCP only when all of the alternative regimens are contraindicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    may be used as an alternative regimen in patients with severe PCP who have failed TMP-SMX or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    . The efficacy of this approach was illustrated in a meta-analysis of salvage treatment of 456 patients with HIV and 41 non-HIV-infected patients with confirmed PCP who did not improve with conventional antipneumocystis therapy (most commonly TMP-SMX or intravenous pentamidine) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/6\">",
"     6",
"    </a>",
"    ]. The combination of clindamycin plus primaquine was the most effective alternative treatment in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cyst wall of P. jirovecii contains beta-D-glucan, the synthesis of which is inhibited by echinocandins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the echinocandins have little documented value in the treatment of PCP in humans, and progression of PCP has been reported in patients receiving echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy for PCP in patients without HIV infection has not been adequately studied, but a 14 day regimen is usually suggested in the literature. In contrast, the duration of therapy is 21 days in patients with HIV infection due to a greater risk of relapse with 14 days of therapy and the greater organism burden and slower clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/9\">",
"     9",
"    </a>",
"    ]. Given the more fulminant presentation and worse outcomes in non-HIV-infected patients, we suggest treating for 21 days despite the lack of evidence supporting this duration. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Outcomes'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-HIV-infected patients with PCP should start to show clinical improvement by the seventh day of therapy. Patients who are not improving after seven days of therapy are considered to have treatment failure and are treated in the same way as HIV-infected patients who fail initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\", section on 'Treatment failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adjunctive glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive glucocorticoids are recommended in HIV-infected patients with moderate or severe PCP because their use improves clinical outcomes and mortality without increasing the risk of other opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\", section on 'Use of corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, there is no clear evidence of efficacy for adjunctive glucocorticoids for the treatment of PCP in HIV-negative patients as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 30 non-HIV-infected patients with severe PCP showed that the 16 patients who received the equivalent of &ge;60 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day had a significantly shorter duration of mechanical ventilation, ICU admission, and supplemental oxygenation than the 14 patients who received the equivalent of &le;30 mg of prednisone per day or were on a glucocorticoid taper [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/10\">",
"       10",
"      </a>",
"      ]. However, similar rates of mechanical ventilation and in-hospital mortality were observed.",
"     </li>",
"     <li>",
"      A second retrospective study of 31 non-HIV-infected patients with PCP also found no difference in the need for mechanical ventilation or mortality between the glucocorticoid-treated and untreated groups [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available limited data do not provide support for the routine use of adjunctive glucocorticoids in non-HIV-infected patients with PCP. On the other hand, the greater degree of inflammation in the lungs of non-HIV-infected patients provides a rationale for glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the fulminant course and high mortality in non-HIV-infected patients with moderate to severe PCP, we suggest the use of glucocorticoid therapy in patients who, while breathing room air, have an arterial blood gas measurement that shows a partial pressure of oxygen &le;70 mmHg or an alveolar-arterial (A-a) oxygen gradient &ge;35 mmHg, or hypoxemia on pulse oximetry. The glucocorticoid regimen is shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\", section on 'Use of corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not meet the above criteria for glucocorticoid therapy but are already being treated for some other reason (eg, graft-versus-host disease) should continue their current regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of appropriate antibiotic therapy, the mortality rate from PCP in non-HIV-infected patients is 90 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/2\">",
"     2",
"    </a>",
"    ]. The outcomes in non-HIV-infected patients treated for PCP are generally worse than in HIV-infected patients; mortality from PCP in patients with HIV infection is approximately 10 to 20 percent compared with 35 to 50 percent in those without HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Patients with cancer have the highest mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Non-HIV-infected patients with PCP also have higher rates of hospitalization and intensive care unit admission [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe PCP is associated with higher mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. As an example, in a retrospective review of 30 non-HIV-infected patients with PCP and respiratory failure, the mortality rate was 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/18\">",
"     18",
"    </a>",
"    ]. Mortality was associated with an elevated APACHE III score on the day of ICU admission, delay in intubation, duration of mechanical ventilation, and the development of pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link&amp;anchor=H5#H5\">",
"     \"Predictive scoring systems in the intensive care unit\", section on 'Acute Physiologic and Chronic Health Evaluation (APACHE)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalized patients with PCP should be assigned to standard precautions, although they should not be placed in the same room with other immunocompromised individuals due to the potential for person-to-person spread [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been published for the use of PCP prophylaxis among patients with cancer, including hematopoietic stem cell transplant (HCT) recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Although there are no published guidelines for the use of PCP prophylaxis among solid organ transplant recipients, it is standard practice to administer prophylaxis in this population. There are no published guidelines for PCP prophylaxis among patients with rheumatologic diseases receiving immunosuppressive drugs, but some advocate its use in such patients when they are receiving high-dose immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of randomized trials of PCP prophylaxis in immunocompromised patients without HIV infection, it was concluded that prophylaxis is warranted when the risk of PCP is higher than 3.5 percent in adults, and might be indicated at lower incidence rates in children since children experience fewer medication-related adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with the following risk factors should receive PCP prophylaxis based upon the evidence for substantial risk of PCP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients receiving a glucocorticoid dose equivalent to &ge;20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for one month or longer who also have another cause of immunocompromise (eg, certain hematologic malignancies or a second immunosuppressive drug) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/1,14,20,25-27\">",
"       1,14,20,25-27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      should receive PCP prophylaxis for a minimum of two months after completion of therapy or until the CD4 count is &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      whichever occurs later [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20,28\">",
"       20,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients receiving concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      and radiotherapy, until recovery of lymphopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20,29\">",
"       20,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with acute lymphocytic leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Allogeneic HCT recipients beginning after engraftment and continuing for as long as immunosuppressive therapy is given [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Selected autologous HCT recipients, including those who have an underlying hematologic malignancy, such as lymphoma, myeloma, or leukemia, especially when intensive treatment or conditioning regimens have included a purine analog (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      ) or high-dose glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Solid organ transplant recipients, often for at least six months to one year following transplantation and during periods of high doses of immunosuppressive medications (eg, during treatment for acute rejection)",
"     </li>",
"     <li>",
"      Patients with certain primary immunodeficiencies (eg, severe combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Some experts also recommend PCP prophylaxis for patients receiving a purine analog, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , or another T-cell depleting agent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Some authorities recommend PCP prophylaxis for patients receiving certain combinations of immunosuppressive drugs. As an example, PCP prophylaxis should be considered in patients treated with TNF-alpha inhibitors who are also receiving high-dose glucocorticoids or other intensive immunosuppression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H21#H21\">",
"       \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Pneumocystis pneumonia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with rheumatologic diseases, prophylaxis is usually given to those who are treated with significant doses of glucocorticoids (eg, &ge;20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily for one month or longer) in combination with a second immunosuppressive drug, particularly a cytotoxic agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ), as is commonly used in granulomatosis with polyangiitis (Wegener&rsquo;s) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/22,23,26,27,32-34\">",
"     22,23,26,27,32-34",
"    </a>",
"    ]. Patients with",
"    <span class=\"nowrap\">",
"     polymyositis/dermatomyositis",
"    </span>",
"    who have interstitial pulmonary fibrosis may be at increased risk for PCP with glucocorticoids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Immunosuppressive drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Rheumatologic diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    alone or in combination with low doses of glucocorticoids, as is often used in rheumatoid arthritis, does not appear to warrant prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, patients with granulomatosis with polyangiitis (Wegener&rsquo;s) receiving methotrexate in combination with high doses of glucocorticoids should receive prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'PCP prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians have been hesitant to use TMP-SMX for PCP prophylaxis in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    due to concern for myelosuppression. However, prophylactic doses of TMP-SMX appear to be safe in patients with granulomatosis with polyangiitis (Wegener&rsquo;s) receiving methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/34,36\">",
"     34,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP prophylaxis should be considered in patients with other conditions that cause immunocompromise based upon their risk of PCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is highly effective and it is therefore considered the first-line agent. This approach has been recommended in several guidelines by major organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/1,20,21,25\">",
"     1,20,21,25",
"    </a>",
"    ]. In a retrospective study from Denmark that identified 50 cases of PCP in patients without HIV infection during 2002-2004, the majority of patients (82 percent) never received PCP prophylaxis, whereas 16 percent had PCP prophylaxis discontinued months prior to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of TMP-SMX prophylaxis was illustrated in a meta-analysis of 12 randomized controlled trials that included 1245 immunocompromised patients without HIV infection who had undergone autologous bone marrow or solid organ transplantation or had a hematologic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/24\">",
"     24",
"    </a>",
"    ]. Two of the trials compared TMP-SMX to another agent with activity against Pneumocystis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    in one trial and sulfadoxine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    in one trial). The remaining trials compared various dosing regimens of TMP-SMX, or compared TMP-SMX to placebo, an agent without activity against Pneumocystis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in renal transplant recipients for urinary tract infection prevention), or no prophylaxis.",
"   </p>",
"   <p>",
"    TMP-SMX prophylaxis was associated with a 91 percent reduction in the occurrence of PCP (RR 0.09, 95% CI 0.02-0.32). The number needed to treat to prevent one infection was 15. Mortality due to PCP was also significantly reduced (RR 0.17, 95% CI 0.03-0.94), although all-cause mortality was not. No differences in efficacy were found between once-daily and thrice-weekly administration schedules for TMP-SMX.",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis in patients with granulomatosis with polyangiitis (Wegener&rsquo;s) receiving immunosuppressive drugs suggested that PCP prophylaxis with TMP-SMX increased quality-adjusted life expectancy and reduced costs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMP-SMX is generally well-tolerated in patients without HIV infection, as a meta-analysis found that adverse events necessitating cessation of therapy occurred in only 3.1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, TMP-SMX has a high rate of adverse effects in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link&amp;anchor=H11#H11\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that can been used for PCP prophylaxis in non-HIV-infected patients include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    , aerosolized or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    , and sulfadoxine plus pyrimethamine (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Randomized trials in non-HIV-infected patients are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One such trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    to TMP-SMX for PCP prophylaxis in 39 patients following autologous hematopoietic stem cell transplantation showed that atovaquone is well-tolerated in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/39\">",
"     39",
"    </a>",
"    ]. No firm conclusions can be reached about the relative efficacy of atovaquone since the number of patients studied was small and no patient in either arm developed PCP.",
"   </p>",
"   <p>",
"    The comparative efficacy of PCP prophylaxis regimens has been more extensively studied in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link&amp;anchor=H6#H6\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Comparative efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is the recommended first-line agent for PCP prophylaxis based upon its proven efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/1,20,21,24,25,27\">",
"     1,20,21,24,25,27",
"    </a>",
"    ]. It may be given as one double-strength tablet daily or three times per week or as one single-strength tablet daily. For those who are intolerant of TMP-SMX, desensitization should be attempted when possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link&amp;anchor=H12#H12\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Rechallenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    as the agent of choice for patients who cannot tolerate TMP-SMX since hematologic toxicity and other serious toxicities are uncommon with atovaquone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    ) is a reasonable alternative. Other possible regimens include aerosolized or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    , and sulfadoxine plus pyrimethamine (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link&amp;anchor=H5#H5\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional benefit of TMP-SMX, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    , is that these regimens provide protection against toxoplasmosis. TMP-SMX also prevents some bacterial infections, such as pneumococcal, nocardial, and listerial infections.",
"   </p>",
"   <p>",
"    PCP prophylaxis should be continued until the risk factor for the disease is no longer present [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/20,21,25\">",
"     20,21,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Caution should be exercised in discontinuation of PCP prophylaxis in patients who have received high-dose glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , since prolonged immunosuppression may persist after discontinuation of such agents. Although the CD4 count has not been shown to correlate with risk of PCP in non-HIV-infected patients, some experts have suggested discontinuing prophylaxis only in patients who have had a CD4 count &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hematopoietic stem cell transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP prophylaxis is typically recommended in allogeneic hematopoietic stem cell transplant (HCT) recipients from engraftment until at least six months after HCT, but for a longer period in patients who continue to receive immunosuppressive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/21\">",
"     21",
"    </a>",
"    ]. PCP prophylaxis is also used in selected autologous HCT recipients, and is typically continued for three to six months following transplant (or longer for those requiring ongoing immunosuppressive drugs). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The preferred regimen for PCP prophylaxis in HCT recipients is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) since it appears to be the most efficacious and because it has activity against several other pathogens, including Toxoplasma gondii, Listeria monocytogenes, and Nocardia spp [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/21\">",
"     21",
"    </a>",
"    ]. Because of concern that TMP-SMP can delay engraftment, it is not usually given until after engraftment has occurred.",
"   </p>",
"   <p>",
"    Alternative regimens include oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , aerosolized or IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    . When TMP-SMX cannot be used, we favor atovaquone since hematologic toxicity and other serious toxicities are uncommon. However, it is significantly more expensive than the other regimens. With respect to dapsone, there are concerns about methemoglobinemia and other hematologic toxicity, although a case-control study in HCT recipients failed to identify any hematologic toxicity with dapsone among patients allergic to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9289/abstract/41\">",
"     41",
"    </a>",
"    ]. The usual dose is 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    but, to minimize toxicity, some use dapsone at a dose of 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    50 mg orally twice weekly. Patients should be tested for glucose-6-phosphate dehydrogenase deficiency before taking dapsone.",
"   </p>",
"   <p>",
"    Other options include aerosolized or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , and sulfadoxine in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    , which is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"     table 2",
"    </a>",
"    ). Patients given pyrimethamine with either sulfadoxine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    should therefore also receive folinic acid. These agents are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link&amp;anchor=H5#H5\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that sulfonamide-containing antibiotics, including TMP-SMX, can cause exacerbations of systemic lupus erythematosus (SLE), particularly in patients with adverse reactions to these agents. As a result, many rheumatologists avoid TMP-SMX prophylaxis in patients with SLE. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    as an alternative agent in such patients who require PCP prophylaxis (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Avoidance of specific medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=see_link\">",
"       \"Patient information: Pneumocystis pneumonia (PCP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     PCP treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumocystis pneumonia (PCP) is a potentially life-threatening infection that occurs in immunocompromised individuals, especially in those with HIV, but also in hematopoietic stem cell and solid organ transplant recipients; those with cancer (particularly hematologic malignancies); and those receiving glucocorticoids, chemotherapeutic agents, and other immunosuppressive medications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) as the preferred medication for the treatment of PCP in patients without HIV infection (",
"      <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild or moderate PCP who are unable to tolerate TMP-SMX, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other drugs for the treatment of mild to moderate PCP include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In patients with severe PCP who are unable to tolerate TMP-SMX, we recommend intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef61052 \" href=\"UTD.htm?21/61/22492\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using adjunctive glucocorticoids in non-HIV-infected patients who, while breathing room air, have an arterial blood gas measurement that shows a partial pressure of oxygen &le;70 mmHg or an alveolar-arterial (A-a) oxygen gradient &ge;35 mmHg, or hypoxemia on pulse oximetry. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Adjunctive glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Outcomes of PCP",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The outcomes for immunocompromised patients without HIV infection treated for PCP are generally worse than in those with HIV infection; mortality from PCP in patients with HIV is approximately 10 to 20 percent compared with 35 to 50 percent in those without HIV. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infection control for PCP",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalized patients with PCP should be assigned to standard precautions, although they should not be placed in the same room with other immunocompromised individuals due to the potential for person-to-person spread. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     PCP prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend PCP prophylaxis for the following high-risk groups: Patients receiving a glucocorticoid dose equivalent to &ge;20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for one month or longer who also have another cause of immunocompromise; allogeneic hematopoietic stem cell and solid organ transplant recipients; patients with acute lymphocytic leukemia; patients receiving certain immunosuppressive drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      in conjunction with radiotherapy); and selected autologous hematopoietic stem cell transplant recipients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest PCP prophylaxis for patients taking purine analogs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest PCP prophylaxis for patients with rheumatologic diseases who are treated with significant doses of glucocorticoids (eg, &ge;20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for one month or longer) in combination with a second immunosuppressive drug, particularly a cytotoxic agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ), as is commonly used in granulomatosis with polyangiitis (Wegener&rsquo;s) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients who require PCP prophylaxis, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) (",
"      <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      for PCP prophylaxis in patients who cannot tolerate TMP-SMX (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using an agent other than TMP-SMX, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      , in patients with systemic lupus erythematosus (SLE) who require prophylaxis due to the risk that TMP-SMX may cause an SLE flare (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/1\">",
"      Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/2\">",
"      Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 1975; 112:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/3\">",
"      Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults. N Engl J Med 1976; 295:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/4\">",
"      Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980; 92:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/5\">",
"      Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978; 92:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/6\">",
"      Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001; 161:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/7\">",
"      Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004; 128:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/8\">",
"      Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 2006; 43:e92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/9\">",
"      Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/10\">",
"      Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/11\">",
"      Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999; 29:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/12\">",
"      Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/13\">",
"      Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/14\">",
"      Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002; 34:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/15\">",
"      Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/16\">",
"      Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/17\">",
"      Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/18\">",
"      Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005; 128:573.",
"     </a>",
"    </li>",
"    <li>",
"     Siegel, JD, Rhinehart, E, Jackson, M, et al. 2007 Guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings, June 2007. file://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf (Accessed July 2, 2008).",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/21\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/22\">",
"      Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/23\">",
"      Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 2008; 59:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/24\">",
"      Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/25\">",
"      Huang L, Morris A, Limper AH, et al. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006; 3:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/26\">",
"      Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995; 155:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/27\">",
"      Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350:2487.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/foi/label/2007/103948s5070lbl.pdf (Accessed on July 02, 2008).",
"    </li>",
"    <li>",
"     Temodar (temozolomide) prescribing information. file://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf (Accessed on February 11, 2013).",
"    </li>",
"    <li>",
"     Stiehm, ER, Ochs, HD, Winkelstein, JA. Immunodeficiency disorders: General considerations. In: Immunological Disorders in Infants and Children, 5th ed, Stiehm, ER, Ochs, HD, Winkelstein, JA (Ed), Elsevier Saunders, Philadephia 2004. p.289.",
"    </li>",
"    <li>",
"     Ochs, HD, Stiehm, ER, Winkelstein, JA. Antibody deficiencies. In: Immunological Disorders in Infants and Children, 5th ed, Stiehm, ER, Ochs, HD, Winkelstein, JA (Ed), Elsevier Saunders, Philadephia 2004. p.357.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/32\">",
"      Li J, Huang XM, Fang WG, Zeng XJ. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol 2006; 12:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/33\">",
"      Meuli K, Chapman P, O'Donnell J, et al. Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Intern Med J 2007; 37:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/34\">",
"      White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006; 66:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/35\">",
"      Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/36\">",
"      Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/37\">",
"      Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007; 39:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/38\">",
"      Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000; 43:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/39\">",
"      Colby C, McAfee S, Sackstein R, et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/40\">",
"      Torre-Cisneros J, De la Mata M, Pozo JC, et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis 1999; 29:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9289/abstract/41\">",
"      Sangiolo D, Storer B, Nash R, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 2005; 11:521.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1393 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-125.39.66.146-9893370942-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9289=[""].join("\n");
var outline_f9_4_9289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adjunctive glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hematopoietic stem cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PCP treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Outcomes of PCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infection control for PCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1393|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/61/22492\" title=\"table 1\">",
"      Treatment of Pneumocystis infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/15/23804\" title=\"table 2\">",
"      PCP prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=related_link\">",
"      Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_4_9290="Cancer pain management with opioids: Prevention and management of side effects";
var content_f9_4_9290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer pain management with opioids: Prevention and management of side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Zankhana Mehta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Ebtesam Ahmed, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/4/9290/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/4/9290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are widely used for treatment of cancer pain because of their safety, multiple routes of administration, ease of titration, reliability, and effectiveness for all types of pain (ie, somatic, visceral, neuropathic). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link&amp;anchor=H8#H8\">",
"     \"Assessment of cancer pain\", section on 'Inferred pathophysiology (types of cancer pain)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioids can produce dose-limiting side effects, the most common of which are constipation and mental clouding. There is marked interindividual variability in the sensitivity to adverse effects from opioids, which may be due to genetic differences, age, comorbidity, or interactions with other drugs.",
"   </p>",
"   <p>",
"    Side effect management is a key element of opioid therapy for cancer pain. Effective treatment of side effects increases the likelihood of a favorable outcome. Side effects are a major contributor to the phenomenon of undertreatment of cancer pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'The problem of undertreatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, there are three approaches to treating adverse effects from opioids: symptomatic management, dose reduction, and changing to a different opioid or route of administration. Although symptomatic management strategies are based upon anecdotal experience or represent an extrapolation of approaches directed against similar symptoms that are caused by other mechanisms, they are widely accepted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H16#H16\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Practical considerations in opioid use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover the prevention and management of specific adverse events in patients receiving opioid therapy for cancer pain. Assessment of cancer pain, an overview of specific cancer pain syndromes, the clinical use of opioid analgesics and non-opioid analgesics (including adjuvant analgesics), and non-pharmacologic methods of cancer pain management are covered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BOWEL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been recognized that opioids affect gastrointestinal motility. These effects usually are manifest as constipation, but bloating, early satiety, and pain are possible.&nbsp;Occasionally, patients develop ileus or a syndrome characterized by a relatively high level of abdominal pain.&nbsp;When pain is significant, the term &ldquo;narcotic bowel syndrome&rdquo; has sometimes been applied [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/1\">",
"     1",
"    </a>",
"    ]. The etiology of pain is unknown. The phenomenon of visceral hyperalgesia is known to occur in functional GI disorders, and it may be that some patients who experience pain do so because the increased non-propulsive motility associated with opioids interacts with this underlying pathophysiology.&nbsp;Although theoretically this syndrome could be related to opioid-induced hyperalgesia, there is no evidence linking them to the same processes. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Opioid-induced hyperalgesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Constipation is the most common and persistent side effect from opioid analgesics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/2\">",
"     2",
"    </a>",
"    ]. Among opioid-treated cancer patients, constipation occurs in approximately 10 to 15 percent, and it significantly impacts quality of life as well as opioid use patterns, resource utilization, and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contributory factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors contribute to the development of constipation in patients receiving opioids for cancer pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opioids bind to specific receptors in the gastrointestinal tract and central nervous system to reduce bowel motility by both direct and anticholinergic mechanisms.",
"     </li>",
"     <li>",
"      Longer gastrointestinal transit time causes excessive water and electrolyte reabsorption from feces, and decreased biliary and pancreatic secretion further dehydrates stool.",
"     </li>",
"     <li>",
"      Concurrent use of other constipating drugs (eg, tricyclic antidepressants), dehydration, advancing age, immobility, metabolic abnormalities (eg, hypercalcemia), chemotherapy (particularly treatment with the vinca alkaloids) and tumor-related bowel obstruction may also contribute. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link&amp;anchor=H36#H36\">",
"       \"Enterotoxicity of chemotherapeutic agents\", section on 'Constipation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all opioid formulations are equally constipating. Although the results of randomized trials are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], two systematic reviews concluded that there is less constipation with transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    than with oral sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    to [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H13#H13\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Fentanyl'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with predisposing factors (eg, advanced age, immobility, poor diet, intraabdominal pathology, neuropathy, hypercalcemia, concurrent use of other constipating drugs) should be considered for prophylactic laxative therapy when opioid treatment is initiated. Conventionally, this is accomplished with a stool softener and contact cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    100 mg orally twice daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    2 tablets at bedtime) or daily administration of an osmotic laxative (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    30 ml daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    two tablespoons daily). In patients who are lactose-intolerant, lactulose may cause excessive gas and abdominal pain, cramping, and bloating; it should be avoided in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If constipation develops or worsens in parallel with changes in the opioid regimen, no further evaluation is needed. However, when there is no clear precipitant, an assessment for alternative or contributory causes should be undertaken. This assessment includes history, physical examination (including a rectal examination), and, as necessary, laboratory evaluation, imaging studies, or colonoscopy. Potentially remediable contributors to constipation should be managed appropriately.",
"   </p>",
"   <p>",
"    Some patients are able to improve bowel function by dietary modifications, including increased consumption of fluids and dietary fiber. Fiber should be discontinued, however, if the patient is debilitated, bowel obstruction is suspected, or hydration has been difficult to maintain. These factors may predispose to the worsening of obstructive symptoms when fiber is introduced into the diet. If possible, physical activity also should be increased. When care must be provided to the patient, privacy and convenience during defecation should be ensured.",
"   </p>",
"   <p>",
"    Patients who have passed no stool in several days and who have no evidence of bowel obstruction or ileus are likely to be impacted. It is often possible to clear the rectal vault and lower sigmoid colon with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    enema followed by an irritant enema, but manual disimpaction may be required. Once an impaction has been ruled out or cleared, laxative therapy may be started.",
"   </p>",
"   <p>",
"    There are numerous options for laxative therapy (",
"    <a class=\"graphic graphic_table graphicRef73845 \" href=\"UTD.htm?13/12/13517\">",
"     table 1",
"    </a>",
"    ) and no data to suggest that any one approach is superior to any other. In a Cochrane systematic review of management of constipation in palliative care patients, four randomized trials comparing different kinds of laxatives showed no significant differences among them [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/12\">",
"     12",
"    </a>",
"    ]. The specific approach selected should be consistent with patient preference (",
"    <a class=\"graphic graphic_table graphicRef60646 \" href=\"UTD.htm?2/28/2508\">",
"     table 2",
"    </a>",
"    ). If one approach is ineffective, an alternative should be tried.",
"   </p>",
"   <p>",
"    A simple oral regimen using an osmotic agent or a contact cathartic is a reasonable starting point, but many other strategies exist. Seldom used, alternative oral strategies include acetylcholinesterase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ), the prostaglandin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management of refractory cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid antagonists may be useful to treat refractory constipation due to opioid agonists. These agents should be avoided in the presence of bowel obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4580064\">",
"    <span class=\"h3\">",
"     Methylnaltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     Methylnaltrexone",
"    </a>",
"    is a peripherally acting opioid antagonist that is specifically approved for opioid-induced constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. It has a restricted ability to cross the blood brain barrier and does not induce symptoms of opioid withdrawal.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    for the treatment of opioid-induced constipation has been shown in three randomized trials and confirmed in a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/12\">",
"     12",
"    </a>",
"    ]. The success rate was approximately 50 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     Methylnaltrexone",
"    </a>",
"    is given subcutaneously once every other day, and the frequency of administration can be increased if needed but should not exceed once daily. The approved dosage is 8 mg for patients weighing 38 to 61 kg, and 12 mg for those weighing 62 to 114 kg; for those outside these ranges, the recommended dose is 0.15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Long-term administration of methylnaltrexone is feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher doses may provide additional benefit, although the data are limited. In the trial described above, a subgroup of 41 patients received dose escalation during the second week of therapy because of limited effectiveness (20 in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    group, 21 in the placebo group at an equivalent volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/13\">",
"     13",
"    </a>",
"    ]. The fraction of patients who had a bowel movement within four hours of increasing the methylnaltrexone dose to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    was 24 percent (compared to 15 percent within four hours of the prior dose of 0.15",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    The corresponding rates in the placebo group were 8 percent before, and 7 percent after dose escalation. The pattern of adverse events in patients who had dose escalation did not differ in either group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4580071\">",
"    <span class=\"h3\">",
"     Oral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    (1 to 12 mg), another opioid antagonist, has also been used to treat constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], but there is less evidence to support its benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, it is 3 percent bioavailable, and for this reason, may reverse systemic opioid effects, and potentially worsen pain or induce withdrawal effects.",
"   </p>",
"   <p>",
"    However, at least some evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    can be given safely to patients with chronic cancer and non-cancer pain in combination with prolonged release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    with less opioid-induced constipation and no compromise in analgesic efficacy or safety compared to oxycodone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A fixed ratio combination of oxycodone plus naloxone is available commercially (Targin&reg; and Targinact&reg;) in Germany and some other countries in Europe.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/7/5236?source=see_link\">",
"     Alvimopan",
"    </a>",
"    is an orally administered peripherally acting mu receptor antagonist that is approved in the US for short-term inpatient management of postoperative ileus in patients undergoing bowel resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link&amp;anchor=H17#H17\">",
"     \"Postoperative ileus\", section on 'Peripheral acting mu-opioid receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/7/5236?source=see_link\">",
"     alvimopan",
"    </a>",
"    for opioid induced constipation was shown in a double-blind randomized trial in which 518 patients with non-cancer pain and opioid-induced bowel dysfunction were randomly assigned to alvimopan 0.5 mg daily or twice daily, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/21\">",
"     21",
"    </a>",
"    ]. Twice daily alvimopan reduced rescue laxative use, and significantly improved the proportion of patients experiencing three or more spontaneous bowel movements with no laxative use in the preceding 24 hours (72 versus 48 percent). Active treatment did not increase the requirement for opioid medication or increase pain intensity scores.",
"   </p>",
"   <p>",
"    The drug was specifically not approved for opioid-induced constipation because an earlier unpublished 12-month safety study in patients treated with opioids for chronic pain had shown more reports of myocardial infarction in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/7/5236?source=see_link\">",
"     alvimopan",
"    </a>",
"    than with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/22\">",
"     22",
"    </a>",
"    ]. Although a causal relationship has not been established, without more information, the use of this drug in the ambulatory setting for opioid-induced constipation cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SOMNOLENCE AND MENTAL CLOUDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy can cause somnolence or mental clouding. Symptoms typically wane over a period of days or weeks, but are persistent in some patients, particularly in those with other contributing factors (eg, early dementia or the use of other centrally acting drugs).",
"   </p>",
"   <p>",
"    The characteristics of drug-induced somnolence and mental clouding can vary widely. The degree of cognitive impairment ranges from slight inattention or fatigue, to befuddlement to disorientation, severe memory impairment, or extreme confusion and delirium. Perceptual disorders, which themselves range from increased dreaming and hypnagogic illusions to frank hallucinations, can occur, as can mood disturbances. In this population, mood disturbance is more often negative (irritability, depressed mood, dysphoria) than positive (contentment, euphoria).",
"   </p>",
"   <p>",
"    The incidence of cognitive dysfunction in patients receiving opioid therapy for cancer pain is not well characterized. A prospective, multicenter cross-sectional study of 1915 adult patients with cancer who received opioids for at least three days suggested that possible or definite cognitive dysfunction (as assessed by Mini Mental Status Examination (MMSE)) scores lower than 27 was present in one-third of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/23\">",
"     23",
"    </a>",
"    ]. Risk factors for cognitive dysfunction included a diagnosis of lung cancer, daily opioid doses (oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    equivalents) of &ge;400 mg, older age, low performance status, and time since cancer diagnosis &lt;15 months; the presence of breakthrough pain was associated with better cognitive function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like other symptoms associated with opioid therapy, the decision to pursue additional evaluation is a clinical judgment that is influenced by the likelihood that other factors may be contributing. If the relationship of the symptoms to the drug or other factors is clear, further evaluation may not be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stepwise approach to management includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obvious contributing causes (eg, primary central nervous system pathology, metabolic disturbances, dehydration, other drugs) should be addressed and treated, if this is feasible and consistent with the goals of care. Nonessential centrally-acting medications should be reduced or eliminated.",
"     </li>",
"     <li>",
"      The opioid regimen should then be evaluated. If analgesia is satisfactory, it may be possible to reduce the dose, but this is often limited by recrudescence of pain. The impact of an empiric 25 percent dose reduction on both pain control and side effects is usually clear within a short time frame.",
"      <br/>",
"      <br/>",
"      On the other hand, if analgesia is unsatisfactory, opioid rotation may be tried, or an adjuvant (coanalgesic) may be initiated in an attempt to achieve an opioid-sparing effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H28#H28\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Using opioid rotation to manage poorly responsive pain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"       \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug treatment directed at the symptom may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a limited clinical literature, mainly anecdotal experience, supporting the use of central nervous system stimulants to offset opioid-induced sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The largest experience is with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    , two agents used commonly for cancer-related fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       Methylphenidate",
"      </a>",
"      &ndash; Benefit for methylphenidate in patients receiving opioids has been suggested in two of three small randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. A systematic review concluded that this represented weak evidence in support of the use of methylphenidate given that the quality of the negative study was lower than that of the two positive studies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/29\">",
"       29",
"      </a>",
"      ]. Furthermore, treatment with methylphenidate was associated with anxiety, hallucinations, and sweating.",
"      <br/>",
"      <br/>",
"      Methylphenidate is typically initiated at a starting dose of 5 mg in the morning and at noon, or a comparable dose of one of the long-acting, modified-release formulations. The dose usually requires titration until benefits occur or side effects supervene. Most patients experience benefit at doses well below 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      but some require considerably higher doses.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       Modafinil",
"      </a>",
"      &ndash; Modafinil, a nonamphetamine psychostimulant, appears to cause fewer sympathomimetic side effects than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      and other psychostimulants. Evidence to support benefit of modafinil to prevent opioid-induced sedation is limited to retrospective reports of patients with pain of nonmalignant origin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Modafanil is initiated at 100 to 200 mg per day and may require dose escalation to optimize effects. Most patients require no more than 600 mg per day and only occasional patients require an afternoon dose.",
"     </li>",
"     <li>",
"      Other psychostimulants &ndash; Other psychostimulants that may be beneficial in the setting of opioid-induced sedation include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/33\">",
"       33",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/44/23238?source=see_link\">",
"       dexmethylphenidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"       atomoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      , and caffeine [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/34\">",
"       34",
"      </a>",
"      ]. A systematic review of treatment for opioid-related CNS symptoms concluded that the quality of the studies involving dexamphetamine, caffeine and donepezil was not sufficient to make any recommendations about their use [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/29\">",
"       29",
"      </a>",
"      ]. These drugs are usually considered only if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      are poorly tolerated or contraindicated. There is very limited clinical experience with the use of the acetylcholinesterase inhibitors, such as donepezil, in the management of this side effect [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapeutic effects of psychostimulants sometimes wane over time. Whether this reflects tolerance or symptom progression is unknown, but the phenomenon should be recognized. Dose escalation of the psychostimulant or a switch to an alternative drug may be useful.",
"   </p>",
"   <p>",
"    All psychostimulants can produce side effects such as tremulousness, insomnia, anorexia, and anxiety, tachycardia, and hypertension. Given the potential for these adverse effects, relative contraindications to the use of psychostimulants include preexisting anorexia, severe insomnia, a psychiatric disorder characterized by anxiety or paranoid ideation, significant cardiac disease, or poorly controlled hypertension. Older patients and those with early dementing illnesses are especially susceptible to untoward psychotomimetic and cognitive disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LESS COMMON SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other side effects are less common but widely recognized opioid-related problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea frequently complicates the initiation of opioid therapy, but tolerance occurs quickly and persistent nausea is infrequent. Gradual rather than rapid upward titration of the opioid dose may prevent persistent nausea. When persistent nausea occurs, it is often in the context of other, less well-characterized gastrointestinal symptoms, including reflux, anorexia, early satiety, and abdominal bloating.",
"   </p>",
"   <p>",
"    Opioids have three potentially emetogenic mechanisms: a direct effect on the chemoreceptor trigger zone, enhanced vestibular sensitivity, and delayed gastric emptying. Refractory constipation and stool impaction may be contributory. When present, they should be managed first.",
"   </p>",
"   <p>",
"    Chronic nausea usually responds to the same group of drug therapies that are used for acute nausea (",
"    <a class=\"graphic graphic_table graphicRef80259 \" href=\"UTD.htm?26/18/26924\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The available evidence supports use of a dopamine antagonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (also a prokinetic drug [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]), or a serotonin receptor antagonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/39,41,42\">",
"     39,41,42",
"    </a>",
"    ], as usual first line agents (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    ). Chronic use of the serotonin receptor antagonists, however, causes constipation, which in itself can be a cause of nausea.",
"   </p>",
"   <p>",
"    The specific clinical scenario may suggest benefit from other strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients who experience nausea with movement or nausea associated with vertigo may respond to an anticholinergic drug such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      or an antihistamine such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"       meclizine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If nausea follows meals or is accompanied by postprandial vomiting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      is an appropriate choice.",
"     </li>",
"     <li>",
"      Patients with epigastric pain or burning should be offered a trial of a proton pump inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      , or an H2 antagonist, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Opioid rotation or a change in route of administration could also be considered. In two small studies, a switch from the oral to the subcutaneous route produced significantly less nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In contrast, there are conflicting data as to the benefit of switching from the oral to the rectal route [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H21#H21\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Selecting the route of administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H28#H28\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Using opioid rotation to manage poorly responsive pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus (uncontrollable spasms of certain muscle groups) is a common dose-related effect of opioids that is often associated with somnolence and mental clouding. The etiology may be multifactorial, with contributions from other drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolic disturbances.",
"   </p>",
"   <p>",
"    The available evidence for treatment of myoclonus comes almost exclusively from published case reports. A systematic review concluded that the available data were insufficient to confirm or refute the benefits of any drug for the management of myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If treatment is considered, the usual approach is to try a low-dose of the benzodiazepine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    (0.5 mg orally every six to eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/49\">",
"     49",
"    </a>",
"    ]) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.5 to 1 mg sublingually or IV q 1 to 2 hours). A trial of an anticonvulsant is rarely considered. A change to another opioid or the addition of an adjuvant analgesic may permit a reduction in opioid dose, relieving the myoclonus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H28#H28\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Using opioid rotation to manage poorly responsive pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Opioid-induced hyperalgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid-induced hyperalgesia is a state of nociceptive sensitization that is caused by exposure to opioids. This state is characterized by a paradoxical response whereby a patient receiving opioids for the treatment of pain may actually become more sensitive to certain painful stimuli and in some cases, experience pain from ordinarily non-painful stimuli (allodynia) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/50\">",
"     50",
"    </a>",
"    ]. The phenomenon of opioid-induced hyperalgesia, linked to the development of analgesic tolerance, has been clearly demonstrated in animal models, and has relevance in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, individual patients who demonstrate a loss of opioid effect in the absence of progressive illness (ie, develop analgesic tolerance), or develop a syndrome of worsening or more diffuse pain, with tremulousness and possibly confusion, during a period of aggressive opioid escalation, may be demonstrating opioid-induced hyperalgesia. Clinicians should be aware of this phenomenon, which often occurs when moaning that arises from delirium at the end of life is mistaken for pain, and extra boluses of opioids are given. All patients with worsening or more diffuse pain during a period of aggressive opioid escalation should be evaluated for delirium and opioid-induced hyperalgesia. When suspected, it is reasonable to consider opioid rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/53\">",
"     53",
"    </a>",
"    ], or the use of a non-opioid strategy for pain control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effects on the hypothalamic-pituitary-adrenal axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids affect the functioning of the hypothalamic-pituitary-adrenal axis, resulting in increased levels of prolactin, decreased levels of sex hormones, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The potential for clinically significant effects related to the decreased levels of sex hormones (ie, sexual dysfunction, infertility, fatigue, accelerated bone loss and mood disturbance) is only now receiving attention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relevance of these issues to patients treated for advanced malignancy is unclear. However, in the setting of less advanced disease, these problems may be relevant to broader efforts to address quality of life concerns. If the goals of care support evaluation, opioid-treated patients with cancer pain who complain of fatigue, depressed mood, or sexual dysfunction should have levels of sex hormones measured. If they are low, and the clinical setting is appropriate, repletion therapy (testosterone in men, estrogen in women) should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Respiratory depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory depression is commonly considered a serious adverse effect of the opioid drugs, but it is rarely a problem when therapy is administered according to accepted guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Tolerance usually develops rapidly to this effect, allowing escalation of the dose by typical increments without clinically significant respiratory effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H27#H27\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may be at risk of clinically significant respiratory depression when opioids are titrated rapidly, when they are administered in the setting of a sleep apnea syndrome or some other serious cardiopulmonary comorbidity that limits ventilatory reserve, or when the opioid is combined with a sedative-hypnotic. Even in the latter setting, however, cautious selection of the initial dose and conservative incremental dose titration limit the risk of respiratory depression.",
"   </p>",
"   <p>",
"    Nonetheless, clinicians should recognize that a syndrome of opioid-induced sleep-disordered breathing is becoming recognized as a risk during long-term opioid therapy. Patients who are predisposed to sleep apnea by virtue of obesity, short neck, or a history of snoring should have opioids administered with particular caution. Other centrally acting drugs, particularly the benzodiazepines, should be added only at low doses and with careful monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients receiving opioids for cancer pain, it is common for staff to attribute any respiratory problem to the opioid. However, opioids produce somnolence and slowed respirations; respiratory distress that is associated with tachypnea and anxiety is never a primary opioid event.",
"   </p>",
"   <p>",
"    It is also essential to recognize that partial reversal of respiratory disturbances by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    in the opioid-treated patient does not mean that the opioid is the primary cause of the problem, particularly if respiratory problems developed during a period of relatively stable dosing. Regardless of a naloxone response, a search for a concurrent acute process (eg, pulmonary embolism, cerebral edema), which may have combined with subclinical opioid effects, is often appropriate in the cancer population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    should not be given to somnolent but easily arousable patients, whether or not they have a respiratory rate less than 10 when sleeping. If hypoventilation and moderate sedation occur near the expected peak of opioid activity, it is best to withhold further opioids until the respiratory rate rises or pain returns. Naloxone should be reserved for symptomatic respiratory depression or for progressive obtundation suggestive of imminent decline. The risks of abstinence, aspiration and severe pain associated with the use of naloxone relatively contraindicate its use in other situations.",
"   </p>",
"   <p>",
"    If needed, it is best to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    using small bolus injections of dilute solution (eg, 1 mL doses of a 0.4 mg diluted in 10 mL saline), which should be titrated against respiratory rate. Repeated doses are often necessary as naloxone's half-life is shorter than that of most opioids. Patients receiving sustained-release opioid formulations or long half-life drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29029?source=see_link\">",
"     levorphanol",
"    </a>",
"    ) may require a naloxone infusion to prevent recurrence of respiratory depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is observed in 2 to 10 percent of patients receiving chronic opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/60\">",
"     60",
"    </a>",
"    ]. The exact mechanism underlying pruritus is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/61\">",
"     61",
"    </a>",
"    ]. In most cases, pruritus does not appear to represent an allergic reaction. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    is reported to cause histamine release from mast cells, other opioids (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    ) are less likely to produce histamine release, yet they are still associated with pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/38,62,63\">",
"     38,62,63",
"    </a>",
"    ]. There is increasing evidence that opioid-induced pruritus is mediated through central mu opioid receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no prospective studies on the treatment of opioid-induced pruritus. Despite the controversy as to the role of histamine in opioid-induced pruritus, antihistamines are commonly used as first-line agents, with varying degrees of success [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/38,61\">",
"     38,61",
"    </a>",
"    ]. Anecdotal experience suggests benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/65\">",
"     65",
"    </a>",
"    ]. Another option is opioid rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low doses of opioid antagonists (eg, nalmefene 10 to 25 micrograms IV,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    1 to 5 mg",
"    <span class=\"nowrap\">",
"     IV/IM)",
"    </span>",
"    are effective for treatment of pruritus in patients with non-cancer pain receiving short-term opioids in the postoperative setting, without reversal of opioid analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/61,67,68\">",
"     61,67,68",
"    </a>",
"    ]. However, long-term use of opioid antagonists in patients with cancer pain who are experiencing prolonged opioid-induced pruritus has not been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19382030\">",
"    <span class=\"h2\">",
"     Allergic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;True opioid allergy is very rare, but both contact dermatitis and systemic hypersensitivity have been reported. Based upon theoretical considerations, it is commonly taught that a patient who continues to need an opioid after demonstrating an allergy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or a semisynthetic opioid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ) should be considered for a trial of one of the synthetic opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ), along with coadministration of a histamine antagonist and a glucocorticoid. However, there is no evidence that cross-sensitivity is reduced by this maneuver as compared to a switch to another alkaloid or semisynthetic opioid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10942457\">",
"    <span class=\"h2\">",
"     Urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids can cause urinary retention. A peripheral effect on nerves that innervate the bladder increasing the tone of the urinary bladder sphincter is possible, and direct binding to spinal opioid receptors causing total bladder relaxation may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preventive strategies have not been established. Although concomitant use of NSAIDs diminishes some opioid side effects (presumably by their opioid sparing effect), there is no impact on urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial management of acute urinary retention consists of prompt relief through catheterization of the bladder. An effort should be made to reduce the dose of drugs that may be contributing to urinary retention, such as drugs with anticholinergic effects.&nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    is effective in reversing urinary retention, but also reverses the analgesic effect in the postoperative setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/74\">",
"     74",
"    </a>",
"    ]. There is a single case report of successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    in the postoperative setting; it was effective at reversing the urinary retention with sustained analgesic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/4/9290/abstract/75\">",
"     75",
"    </a>",
"    ]. Anecdotally, some patients appear to respond to drugs used to treat urinary retention related to prostatic hypertrophy, such as the alpha-1 blockers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link&amp;anchor=H5#H5\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on 'Alpha-1-adrenergic antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy is the first-line approach for moderate or severe chronic cancer pain. Opioids can produce dose-limiting side effects, the most common of which are constipation and mental clouding. Effective treatment of side effects increases the likelihood of a favorable outcome, and side effect management is a key element of opioid therapy for cancer pain.",
"   </p>",
"   <p>",
"    In general, there are three approaches to treating adverse effects from opioids: symptomatic management, dose reduction, or changing to a different opioid or route of administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H16#H16\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Practical considerations in opioid use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prevention and management of constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and persistent side effect from opioid analgesics is constipation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Bowel issues'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    For all patients with predisposing factors, including advanced age, immobility, poor diet, intraabdominal pathology, neuropathy, hypercalcemia, or use of other constipating drugs, we suggest prophylactic laxative therapy when opioid treatment is initiated (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). We prefer the coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    (100 mg orally twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    (two tablets at bedtime).",
"   </p>",
"   <p>",
"    For patients who develop constipation despite the use of a prophylactic bowel regimen, a diagnostic evaluation (including a rectal examination) should be pursued if there is no clear precipitant (eg, a recent increase in dose).",
"    <br/>",
"    <br/>",
"    Once obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaction are ruled out or cleared, laxative therapy may be started. There are numerous options (",
"    <a class=\"graphic graphic_table graphicRef73845 \" href=\"UTD.htm?13/12/13517\">",
"     table 1",
"    </a>",
"    ) and no data to suggest that any one approach is superior to any other. The specific approach selected should be consistent with patient preference (",
"    <a class=\"graphic graphic_table graphicRef60646 \" href=\"UTD.htm?2/28/2508\">",
"     table 2",
"    </a>",
"    ). We start with a simple oral regimen using an osmotic agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    [except in lactose-intolerant patients],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    ) or a contact cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    ). If one approach is ineffective, an alternative should be tried.",
"    <br/>",
"    <br/>",
"    Some cancer patients are able to improve bowel function by dietary modifications (increased consumption of fluids and soluble dietary fiber) and increased physical activity. Fiber should not be increased if the patient is debilitated, bowel obstruction is suspected, or hydration has been difficult to maintain. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prevention and management'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    For refractory constipation due to opioid agonists, we recommend treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Management of refractory cases'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sedation and cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy can cause somnolence or mental clouding, which typically wanes over a period of days or weeks, but is persistent in some patients. The severity is widely variable.",
"   </p>",
"   <p>",
"    A stepwise approach to treatment includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obvious contributing causes should be treated, if feasible and consistent with the goals of care.",
"     </li>",
"     <li>",
"      If analgesia is satisfactory, an empiric trial of opioid dose reduction is a reasonable first step. If analgesia is unsatisfactory, opioid rotation may be beneficial, or coanalgesics may be initiated or increased in order to achieve an opioid-sparing effect.",
"     </li>",
"     <li>",
"      As an alternative strategy, we suggest an empiric trial of a psychostimulant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Psychostimulants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of other opioid-induced side effects is empiric.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nausea frequently complicates the initiation of opioid therapy, but tolerance occurs quickly; persistent nausea is infrequent. Chronic nausea usually responds to the same group of drug therapies that are used for acute nausea (",
"      <a class=\"graphic graphic_table graphicRef80259 \" href=\"UTD.htm?26/18/26924\">",
"       table 3",
"      </a>",
"      ). Other options include a change to the subcutaneous route of administration, or opioid rotation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nausea and vomiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myoclonus is a spasm of certain muscle groups that is typically associated with high-doses of opioids. Therapeutic options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      0.5 mg orally every six to eight hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.5 to 1 mg orally, sublingually or intravenously every two to three hours, an anticonvulsant, or opioid rotation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The phenomenon of opioid-induced hyperalgesia should be considered in the individual patient who demonstrates worsening pain with tremulousness, and possibly generalized allodynia and confusion, as the opioid dose is aggressively escalated, especially if there is no evidence of rapidly progressive illness or new pathology. Therapeutic options include opioid rotation or a switch to a non-opioid analgesic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Opioid-induced hyperalgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory depression is commonly considered a serious adverse effect of the opioid drugs, but it is rarely a problem when therapy is administered according to accepted guidelines. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Respiratory depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioid induced pruritus affects up to 10 percent of patients treated with opioids. Options for management include antihistamines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , or opioid rotation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pruritus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/1\">",
"      Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/2\">",
"      Clemens KE, Klaschik E. Management of constipation in palliative care patients. Curr Opin Support Palliat Care 2008; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/3\">",
"      Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother 2009; 23:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/4\">",
"      Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/5\">",
"      Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009; 13:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/6\">",
"      Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/7\">",
"      van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003; 19:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/8\">",
"      Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/9\">",
"      Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009; 25:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/10\">",
"      Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/11\">",
"      Teuri U, Vapaatalo H, Korpela R. Fructooligosaccharides and lactulose cause more symptoms in lactose maldigesters and subjects with pseudohypolactasia than in control lactose digesters. Am J Clin Nutr 1999; 69:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/12\">",
"      Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011; :CD003448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/13\">",
"      Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/14\">",
"      Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008; 35:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/15\">",
"      McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med 2008; 9:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/16\">",
"      Dutka J, Lowe SS, Michaud M, Watanabe S. Long-term use of methylnaltrexone for the management of constipation in advanced cancer. J Support Oncol 2009; 7:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/17\">",
"      Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992; 52:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/18\">",
"      Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/19\">",
"      Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/20\">",
"      Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/21\">",
"      Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     Alvimopan prescribing information available online at file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=33202&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30a9ea6200406e283f (Accessed on September 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/23\">",
"      Kurita GP, Sj&oslash;gren P, Ekholm O, et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 2011; 29:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/24\">",
"      Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 2005; 39:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/25\">",
"      Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002; 20:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/26\">",
"      Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/27\">",
"      Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/28\">",
"      Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/29\">",
"      Stone P, Minton O. European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med 2011; 25:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/30\">",
"      Cox JM, Pappagallo M. Modafinil: a gift to portmanteau. Am J Hosp Palliat Care 2001; 18:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/31\">",
"      Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/32\">",
"      Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006; 2:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/33\">",
"      Kreeger L, Duncan A, Cowap J. Psychostimulants used for opioid-induced drowsiness. J Pain Symptom Manage 1996; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/34\">",
"      Mercadante S, Serretta R, Casuccio A. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manage 2001; 21:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/35\">",
"      Slatkin NE, Rhiner M, Bolton TM. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manage 2001; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/36\">",
"      Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003; 26:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/37\">",
"      Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 2009; 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/38\">",
"      McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003; 4:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/39\">",
"      Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 2002; 10:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/40\">",
"      Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med 2011; 25:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/41\">",
"      Sussman G, Shurman J, Creed MR, et al. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther 1999; 21:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/42\">",
"      Chung F, Lane R, Spraggs C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol 1999; 16:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/43\">",
"      Ferris FD, Kerr IG, Sone M, Marcuzzi M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manage 1991; 6:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/44\">",
"      Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/45\">",
"      McDonald PP, Graham M, Clayton A, et al. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med 1991; 5:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/46\">",
"      De Conno F, Ripamonti C, Saita L, et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/47\">",
"      Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 1998; 38:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/48\">",
"      Bruera E, Fainsinger R, Spachynski K, et al. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/49\">",
"      Eisele JH Jr, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 49:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/50\">",
"      Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/51\">",
"      Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/52\">",
"      Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009; 12:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/53\">",
"      Induru RR, Davis MP. Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care 2009; 26:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/54\">",
"      Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain 2009; 25:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/55\">",
"      Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010; 26:374.",
"     </a>",
"    </li>",
"    <li>",
"     American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 6th, American Pain Society, Glenview, IL 2008.",
"    </li>",
"    <li>",
"     Fine P, Portenoy RK. Opioid analgesia. New York: McGraw Hill, 2004. file://www.stoppain.org/pcd/content/forpros/opioidbook.asp (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/58\">",
"      Quigley C. Opioids in people with cancer-related pain. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     American Academy of Hospice and Palliative Medicine www.aahpm.org/certification/index.html (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/61\">",
"      Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus. Drugs 2007; 67:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/62\">",
"      Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/63\">",
"      Warner MA, Hosking MP, Gray JR, et al. Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions. J Cardiothorac Vasc Anesth 1991; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/64\">",
"      Ko MC, Song MS, Edwards T, et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004; 310:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/65\">",
"      Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998; 16:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/66\">",
"      Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007; 3:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/67\">",
"      Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001; 35:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/68\">",
"      Yuan CS, Foss JF, O'Connor M, et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998; 52:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/69\">",
"      Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008; 31:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/70\">",
"      Chen YP, Chen SR, Pan HL. Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways. J Pharmacol Exp Ther 2005; 314:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/71\">",
"      Meyboom RH, Brodie-Meijer CC, Diemont WL, van Puijenbroek EP. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999; 8 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/72\">",
"      Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 2005; 102:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/73\">",
"      R&oslash;msing J, M&oslash;iniche S, Mathiesen O, Dahl JB. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiol Scand 2005; 49:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/74\">",
"      Wang J, Pennefather S, Russell G. Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br J Anaesth 1998; 80:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/4/9290/abstract/75\">",
"      Malinovsky JM, Lepage JY, Karam G, Pinaud M. Nalbuphine reverses urinary effects of epidural morphine: a case report. J Clin Anesth 2002; 14:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2800 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9290=[""].join("\n");
var outline_f9_4_9290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BOWEL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contributory factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management of refractory cases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4580064\">",
"      - Methylnaltrexone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4580071\">",
"      - Oral agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SOMNOLENCE AND MENTAL CLOUDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LESS COMMON SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Opioid-induced hyperalgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effects on the hypothalamic-pituitary-adrenal axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Respiratory depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19382030\">",
"      Allergic reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10942457\">",
"      Urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prevention and management of constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sedation and cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/12/13517\" title=\"table 1\">",
"      Agents opioid constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/28/2508\" title=\"table 2\">",
"      Mgmt opioid constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/18/26924\" title=\"table 3\">",
"      Antiem drugs opioid nausea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_4_9291="Mesenteric disease terms";
var content_f9_4_9291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nomenclature used in the medical literature for idiopathic primary inflammatory and fibrotic processes of the mesentery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sclerosing mesenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retractile mesenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric Weber-Christian disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xanthogranulomatous mesenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric lipogranuloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposclerotic mesenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory pseudotumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroperitoneal xanthogranuloma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9291=[""].join("\n");
var outline_f9_4_9291=null;
var title_f9_4_9292="Back pain generating tissue";
var content_f9_4_9292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tissues in the low back that can generate pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        External Tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Subcutaneous tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Capsules of facet and sacroiliac joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ligaments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Longitudinal spinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Posterior interspinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Sacroiliac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Ligamentum flavum (minimal pain fiber innervation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Periosteum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Vertebral bodies and arches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dura mater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural fibro-adipose tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annulus fibrosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arterioles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Of spinal and sacroiliac joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Of vertebral cancellous bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Epidural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Paravertebral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Paravertebral muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Pain fibers in perivascular connective tissues",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kerry Levin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9292=[""].join("\n");
var outline_f9_4_9292=null;
var title_f9_4_9293="Amsterdam Forum Guide B";
var content_f9_4_9293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amsterdam forum guidelines for screening living potential kidney donors - 2",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urine analysis for blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with persistent microscopic hematuria should not be considered for kidney donation unless urine cytology and a complete urologic work up are performed. If urological malignancy and stone disease are excluded, a kidney biopsy may be indicated to rule out glomerular pathology, such as IgA nephropathy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individuals with a history of diabetes or fasting blood glucose &ge;126 mg/dL (7.0 nmol/L) on at least two occasions (or 2-hr glucose with OGTT &ge;200 mg/dL (11.1 mmol/L) should not donate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stone disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        An asymptomatic potential donor with history of a single stone may be suitable for kidney donation if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No hypercalcuria, hyperuricemia, or metabolic acidosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No cystinuria, or hyperoxaluria.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No urinary tract infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If multiple stones or nephrocalcinosis are not evident on CT.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        An asymptomatic potential donor with a current single stone may be suitable if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The donor meets the criteria shown previously for single stone formers and current stone &lt;1.5 cm in size, or potentially removable during the transplant.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Stone formers who should not donate are those with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nephrocalcinosis on x-ray or bilateral stone disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stone types with high recurrence rates, and are difficult to prevent (see text).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A prior history of the following malignancies usually excludes live kidney donation: melanoma, testicular cancer, renal cell carcinoma, choriocarcinoma, hematological malignancy, bronchial cancer, breast cancer and monoclonal gammopathy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A prior history of malignancy may only be acceptable for donation if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prior treatment of the malignancy does not decrease renal reserve or place the donor at increased risk for ESRD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prior treatment of malignancy does not increase the operative risk of nephrectomy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A prior history of malignancy usually excludes live kidney donation but may be acceptable if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The specific cancer is curable and potential transmission of cancer can reasonably be excluded.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urinary tract infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The donor urine should be sterile prior to donation; asymptomatic bacteria should be treated per donation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyuria and hematuria at the proposed time of donation is a contraindication to donation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained hematuria or pyuria necessitates evaluation for adenovirus, tuberculosis, and cancer.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tuberculosis or cancer are contraindications to donation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BP: blood pressure; ABPM: ambulatory blood pressure monitoring; GFR: glomerular filtration rate; BMI: body mass index; BSA: body surface area; CT: computed tomography; ESRD: end-stage renal disease; HLA: human leukocyte antigen.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation 2005; 79:S53. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9293=[""].join("\n");
var outline_f9_4_9293=null;
var title_f9_4_9294="Rx entero endocarditisII";
var content_f9_4_9294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to enterococcal strains resistant to penicillin and susceptible to aminoglycoside and vancomycin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        British Society for Antimicrobial Chemotherapy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult",
"        <br/>",
"        (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric",
"        <br/>",
"        (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          &beta;-Lactamase producing:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24&nbsp;hours IV or IM in&nbsp;three equally divided doses for&nbsp;six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin-sulbactam",
"         <sup>",
"          &Delta;",
"         </sup>",
"         12 g per 24 hours IV in&nbsp;four equally divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two equally divided doses for six weeks; not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          &beta;-Lactamase producing:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;three equally divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin-sulbactam",
"         <sup>",
"          &Delta;",
"         </sup>",
"         300 mg/kg per 24 hours IV in&nbsp;four divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         40 mg/kg per 24 hours IV in&nbsp;two or&nbsp;three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &yen;",
"         </sup>",
"         1 mg/kg IV every 8 to 12 hours for &ge;4 weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         1 g IV every 12 hours for &ge;4 weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Teicoplanin",
"         <sup>",
"          ������",
"         </sup>",
"         10 mg/kg IV once daily for &ge;4 weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          &beta;-Lactamase producing:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;two or&nbsp;three equally divided doses for&nbsp;four to&nbsp;six weeks",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin-sulbactam",
"         <sup>",
"          &Delta;",
"         </sup>",
"         12 g per 24 hours (or 300 mg/kg per 24 hours) IV in&nbsp;four equally divided doses for four&nbsp;to six weeks",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin-clavulanate",
"         <sup>",
"          &Delta;",
"         </sup>",
"         200 mg/kg (amoxicillin component) per 24 hours IV in&nbsp;six equally divided doses for&nbsp;four to&nbsp;six weeks",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two equally divided doses for&nbsp;six weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Intrinsic penicillin resistance",
"         </strong>",
"         <sup>",
"          &sect;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Intrinsic penicillin resistance",
"         </strong>",
"         <sup>",
"          &sect;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         40 mg/kg per 24 hours IV in&nbsp;two or three&nbsp;divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Intrinsic penicillin resistance",
"         </strong>",
"         <sup>",
"          &sect;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two equally divided doses for&nbsp;six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;two or&nbsp;three equally divided doses for&nbsp;six weeks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly.",
"     <br>",
"      * Pediatric doses (should not exceed adult doses): amoxicillin-clavulanate 300 mg/kg (amoxicillin component) per 24 hours IV in&nbsp;four or six divided doses; ampicillin-sulbactam, gentamicin and vancomycin dosing are same as recommended by American Heart Association, pediatric.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Renal function and serum gentamicin concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3 to 4 mcg/mL, trough &lt;1 mcg/mL.",
"       <br>",
"        &Delta; If strain is gentamicin resistant, then &gt;6 weeks of ampicillin-sulbactam or amoxicillin-clavulanate therapy will be needed.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Vancomycin therapy only recommended for patients unable to tolerate penicillins or intrinsic penicillin resistance; vancomycin dose adjusted for peak serum concentrations (one hour after infusion) of 30 to 45 mcg/mL and trough concentration of 10 to 15 mcg/mL.",
"         <br>",
"          &sect; Consultation with a specialist in infectious diseases recommended.",
"          <br>",
"           &yen; If gentamicin-susceptible (MIC &le;128 mg/L).",
"           <br>",
"            &Dagger; Alternative for penicillin-allergic patient provided isolate is teicoplanin susceptible (MIC &le;4 mg/L).",
"            <br>",
"             &dagger;&nbsp;Four weeks of&nbsp;therapy recommended for patients with symptoms of illness &le;3 months;&nbsp;six weeks of&nbsp;therapy recommended for patients with symptoms &gt;3 months. Intravenous amoxicillin-clavulanate is not available in United States.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2004; 54:971; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9294=[""].join("\n");
var outline_f9_4_9294=null;
var title_f9_4_9295="Armpit stretch PI";
var content_f9_4_9295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Armpit stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use your good arm to lift the affected arm onto a shelf, dresser, or other object that is chest high. Gently bend at the knees, so that your armpit stretches open. Try to push the arm up a little bit farther with each stretch. Repeat this stretch 10 to 20 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_4_9295=[""].join("\n");
var outline_f9_4_9295=null;
